dslogo
azlogo

DESTINY-Breast02: Summary

DESTINY-Breast02 confirms the favorable benefit/risk profile of T-DXd in patients with advanced HER2 positive metastatic BC, as previously demonstrated by DESTINY-Breast01

  • In DESTINY-Breast02, T-DXd demonstrated statistically significant and clinically meaningful improvement in PFS and OS vs TPC for patients with HER2 positive metastatic BC previously treated with T‑DM11
  • mPFS results showed T-DXd reduced the risk of progression or death compared with TPC (mPFS of 17.8 and 6.9 months, respectively; HR, 0.3589; 95% CI, 0.2840-0.4535; p<0.000001). mOS results showed T-DXd reduced the risk of death compared with TPC (mOS of 39.2 and 26.5 months, respectively; HR, 0.6575; 95% CI; 0.5023-0.8605; p=0.0021)1
  • The overall safety profile was consistent with the established safety of T-DXd, with no new safety signals observed
  • Overall incidence of ILD for T-DXd in DESTINY-Breast02 was 10.4% (grade 1/2 events, 9.2%).1 Fewer grade 5 ILD events were observed in DESTINY-Breast02 (0.5%) compared with DESTINY-Breast01 (2.7%)2,3

Abbreviations

BC = breast cancer

;

HER2 = human epidermal growth factor receptor 2

;

HR = hazard ratio

;

ILD = interstitial lung disease

;

mOS = median overall survival

;

mPFS = median progression-free survival

;

OS = overall survival 

;

PFS = progression-free survival 

;

T-DM1 = trastuzumab emtansine

;

T-DXd = trastuzumab deruxtecan

;

TPC = treatment of physician's choice

References

1. Krop IE, Park YH, Kim S-B, et al. Trastuzumab deruxtecan vs physician’s choice treatment in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: results from the randomized, phase 3 DESTINY Breast02 trial. Presentation presented at: San Antonio Breast Cancer Symposium 2022; December 6-10, 2022; San Antonio, TX. Presentation GS2-01.
2. Modi S, Saura C, Yamashita T, et al. Updated results from DESTINY-Breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer [poster and abstract]. Poster presented at: San Antonio Breast Cancer Symposium; December 8-11, 2020. Cancer Res. 2021;81(suppl 4). Abstract PD3-06.
3. Saura C, Modi S, Krop I, et al. Trastuzumab Deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer: updated survival results from a phase 2 trial (DESTINY-Breast01) [poster and abstract]. Poster presented at: European Society for Medical Oncology (ESMO) 2021 Annual Meeting; September 16-21, 2021. Ann Oncol. 2021;32(suppl 5). Abstract 279P.

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

To help us improve our content for health care professionals, please take this short survey.

Feedback Survey

©2023 AstraZeneca. All rights reserved.